$ADVM
Adverum Biotechnologies, Inc. Stock $advm

$advm Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009293 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$7.500M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.86M	$9.040M
YoY Change	75.44%	62.01%
% of Gross Profit
Research & Development	$19.98M	$14.75M
YoY Change	35.45%	45.6%
% of Gross Profit
Depreciation & Amortization	$1.170M	$600.0K
YoY Change	95.0%	39.53%
% of Gross Profit
Operating Expenses	$36.14M	$23.79M
YoY Change	51.92%	51.47%
Operating Profit	-$28.64M	-$23.79M
YoY Change	20.39%	51.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$207.0K	$885.0K
YoY Change	-76.61%	-27.34%
Pretax Income	-$28.44M	-$22.91M
YoY Change	24.12%	58.11%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$28.44M	-$22.91M
YoY Change	24.14%	58.09%
Net Earnings / Revenue	-379.15%
Basic Earnings Per Share	-$0.29
Diluted Earnings Per Share	-$0.29	-$310.4K
COMMON SHARES
Basic Shares Outstanding	97.75M shares
Diluted Shares Outstanding	97.75M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$404.0M	$297.1M
YoY Change	35.98%	56.78%
Cash & Equivalents	$45.42M	$130.2M
Short-Term Investments	$358.6M	$166.9M
Other Short-Term Assets	$5.800M	$3.400M
YoY Change	70.59%	-5.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$409.9M	$300.4M
YoY Change	36.41%	55.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.38M	$26.73M
YoY Change	6.18%	0.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$493.0K	$19.00K
YoY Change	2494.74%	-98.42%
Total Long-Term Assets	$51.70M	$48.15M
YoY Change	7.36%	72.58%
TOTAL ASSETS
Total Short-Term Assets	$409.9M	$300.4M
Total Long-Term Assets	$51.70M	$48.15M
Total Assets	$461.6M	$348.6M
YoY Change	32.4%	57.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.056M	$4.663M
YoY Change	-55.91%	159.06%
Accrued Expenses	$17.90M	$12.10M
YoY Change	47.93%	35.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.92M	$16.77M
YoY Change	18.82%	58.18%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.114M	$126.0K
YoY Change	784.13%	-41.67%
Total Long-Term Liabilities	$1.114M	$126.0K
YoY Change	784.13%	-41.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.92M	$16.77M
Total Long-Term Liabilities	$1.114M	$126.0K
Total Liabilities	$46.73M	$44.65M
YoY Change	4.67%	35.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$531.0M	-$407.9M
YoY Change	30.18%
Common Stock	$946.1M	$712.7M
YoY Change	32.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$414.8M	$304.0M
YoY Change
Total Liabilities & Shareholders Equity	$461.6M	$348.6M
YoY Change	32.4%	57.74%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$28.44M	-$22.91M
YoY Change	24.14%	58.09%
Depreciation, Depletion And Amortization	$1.170M	$600.0K
YoY Change	95.0%	39.53%
Cash From Operating Activities	-$22.31M	-$13.62M
YoY Change	63.81%	3.02%
INVESTING ACTIVITIES
Capital Expenditures	$1.404M	$4.210M
YoY Change	-66.65%	92.59%
Acquisitions
YoY Change
Other Investing Activities	$7.980M	-$66.53M
YoY Change	-111.99%	-1449.49%
Cash From Investing Activities	$6.579M	-$70.74M
YoY Change	-109.3%	-2677.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.694M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.505M	$148.6M
YoY Change	-98.99%	-40268.65%
NET CHANGE
Cash From Operating Activities	-$22.31M	-$13.62M
Cash From Investing Activities	$6.579M	-$70.74M
Cash From Financing Activities	$1.505M	$148.6M
Net Change In Cash	-$14.22M	$64.27M
YoY Change	-122.13%	-692.74%
FREE CASH FLOW
Cash From Operating Activities	-$22.31M	-$13.62M
Capital Expenditures	$1.404M	$4.210M
Free Cash Flow	-$23.71M	-$17.83M
YoY Change	33.0%	15.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
CY2021Q1	dei	City Area Code CityAreaCode	650
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001501756
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:LicenseMember
CY2021Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:LicenseMember
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36579
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Adverum Biotechnologies, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5258327
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 Saginaw Drive,
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	656-9323
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021Q1	dei	Trading Symbol TradingSymbol	ADVM
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97934777	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45422000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62424000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	358596000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	367305000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5837000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4709000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	409855000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	434438000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19044000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19376000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28379000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	3780000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	493000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2021Q1	us-gaap	Assets Assets	461551000	USD
CY2020Q4	us-gaap	Assets Assets	482567000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2056000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2810000	USD
CY2021Q1	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13355000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4512000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4473000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19923000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20871000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	25694000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26235000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1114000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1114000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	46731000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	48220000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	946098000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	937134000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-316000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-261000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-530972000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-502536000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	414820000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461551000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	482567000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19980000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14751000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16163000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9040000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	36143000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	23791000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28643000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23791000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	207000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	885000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28436000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-22000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-33000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28491000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23014000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	97750000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	73797000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7224000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1689000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-33000	USD
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-22000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28436000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	414820000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3409000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	332000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140873000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9650000	USD
CY2020Q1	advm	Warrants Issued During Period Shares WarrantsIssuedDuringPeriodShares	7000	shares
CY2020Q1	advm	Stock Paid Value For Tax Withholding For Share Based Compensation StockPaidValueForTaxWithholdingForShareBasedCompensation	1922000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-54000	USD
CY2020Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-54000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	303953000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-28436000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-22906000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1166000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	599000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7224000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3409000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-855000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	179000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	42000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	48000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1279000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6345000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	464000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8000	USD
CY2021Q1	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-332000	USD
CY2020Q1	advm	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-557000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-763000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2514000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-396000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3429000	USD
CY2021Q1	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-502000	USD
CY2020Q1	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-470000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22305000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13616000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	82667000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	127733000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	90650000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	61200000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1404000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4210000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6579000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70743000	USD
CY2021Q1	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	1694000	USD
CY2020Q1	advm	Proceeds From Offerings Of Common Stock Net Of Issuance Costs ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts	140923000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9650000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1922000	USD
CY2021Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	240000	USD
CY2020Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	27000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1505000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	148624000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14221000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64265000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63423000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66896000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49202000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131161000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45422000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130162000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	3780000	USD
CY2020Q1	us-gaap	Restricted Cash RestrictedCash	999000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49202000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131161000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	805000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3474000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-531000000.0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	404000000.0	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other </span></div>market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.
CY2021Q1	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	41843000	USD
CY2021Q1	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2021Q1	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	1000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	41842000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	358506000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	116000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	358596000	USD
CY2020Q4	advm	Cash And Cash Equivalent Amortized Cost CashAndCashEquivalentAmortizedCost	58894000	USD
CY2020Q4	advm	Cash And Cash Equivalent Gross Unrealized Gain CashAndCashEquivalentGrossUnrealizedGain	0	USD
CY2020Q4	advm	Cash And Cash Equivalent Gross Unrealized Loss CashAndCashEquivalentGrossUnrealizedLoss	3000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	58891000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	367191000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	121000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	367305000	USD
CY2021Q1	advm	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears	7000000.0	USD
CY2021Q1	advm	Other Than Temporary Impaired Investments Available For Sale Securities OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities	0	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7500000	USD
CY2020Q4	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	2844000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39609000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37797000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11230000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10072000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28379000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5644000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8344000	USD
CY2021Q1	advm	Accrued Preclinical Clinical And Development Process Costs AccruedPreclinicalClinicalAndDevelopmentProcessCosts	4033000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2759000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1075000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	919000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1325000	USD
CY2021Q1	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13355000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10432000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.65
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3301000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.92
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.86
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	375000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.00
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13349000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.04
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4559000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.41
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7224000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3409000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	200000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected	2	grantee
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14107000	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9932000	shares

Files In Submission

Name	View Source	Status
0001628280-21-009293-index-headers.html	Edgar Link	pending
0001628280-21-009293-index.html	Edgar Link	pending
0001628280-21-009293.txt	Edgar Link	pending
0001628280-21-009293-xbrl.zip	Edgar Link	pending
advm-20210331.htm	Edgar Link	pending
advm-20210331.xsd	Edgar Link	pending
advm-20210331ex101aosborne.htm	Edgar Link	pending
advm-20210331ex102aosborne.htm	Edgar Link	pending
advm-20210331ex103tleungse.htm	Edgar Link	pending
advm-20210331ex104tleungco.htm	Edgar Link	pending
advm-20210331ex105leasenor.htm	Edgar Link	pending
advm-20210331ex106nonxempl.htm	Edgar Link	pending
advm-20210331ex107nonxempl.htm	Edgar Link	pending
advm-20210331ex311.htm	Edgar Link	pending
advm-20210331ex312.htm	Edgar Link	pending
advm-20210331ex321.htm	Edgar Link	pending
advm-20210331ex322.htm	Edgar Link	pending
advm-20210331_cal.xml	Edgar Link	unprocessable
advm-20210331_def.xml	Edgar Link	unprocessable
advm-20210331_htm.xml	Edgar Link	completed
advm-20210331_lab.xml	Edgar Link	unprocessable
advm-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image1.jpg	Edgar Link	pending
image2.jpg	Edgar Link	pending
image3.jpg	Edgar Link	pending
image4.jpg	Edgar Link	pending
image5.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADVM
Adverum Biotechnologies, Inc. Stock $advm

2021 Q1 Form 10-Q Financial Statement

#000162828021009293 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM Adverum Biotechnologies, Inc. Stock $advm

2021 Q1 Form 10-Q Financial Statement

#000162828021009293 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM
Adverum Biotechnologies, Inc. Stock $advm